Search

Aims Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients. Methods and results The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to <18 years with SVTs of various aetiologies received landiolol as a continuous intravenous infusion starting with 5 μg/kg/min titrated up to 40 μg/kg/min depending on heart rate (HR) reduction for up to a maximum of 24 h. The primary endpoint was restoration of normal sinus rhythm (NSR) within 210 min of infusion start. The primary endpoint was achieved in 15 (25.0%) patients. A total of 24 (40.0%) patients achieved a HR reduction of at least 20% within 210 min of landiolol infusion. A significant HR reduction was observed within minutes post-infusion, with a mean (±SD) reduction after 210 min of −13.2 (±11.5)% (P < 0.0001) in the overall population. By infusion end, 51.7% of patients achieved HR reduction of at least 20% from baseline and/or NSR conversion. The PK characteristics were consistent with the known profile of landiolol among adults. The most common adverse drug reaction was hypotension (10%). Conclusion Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported. Clinical Trial Registration EU Clinical Trial Register; EudraCT Number: 2015-001129-17. [ABSTRACT FROM AUTHOR]

Die Fähigkeit, Herausforderungen und Probleme im Alltag erfolgreich zu bewältigen, gilt als wesentliche Facette von Resilienz und schützt Heranwachsende während ihrer gesamten Entwicklung. Zwei Möglichkeiten, sozial-kognitive Problemlösefähigkeiten im Vorschulalter zu erfassen, werden methodisch vorgestellt und empirisch mit der häuslichen Lernumwelt in Beziehung gesetzt. Die Daten stammen aus dem Verbundprojekt „Lernunterstützung durch kognitive Aktivierung in inklusiven Kitas (KoAkiK)". The ability to successfully cope with challenges and problems in everyday life is considered an essential facet of resilience and protects children and youths throughout their development. Two ways of capturing social-cognitive problem-solving skills in preschool age will first be methodically presented and then empirically related to the home learning environment. The data originate from the joint project "cognitive activation in inclusive child care centers (KoAkiK)". [ABSTRACT FROM AUTHOR]

Die Fähigkeit, Herausforderungen und Probleme im Alltag erfolgreich zu bewältigen, gilt als wesentliche Facette von Resilienz und schützt Heranwachsende während ihrer gesamten Entwicklung. Zwei Möglichkeiten, sozial-kognitive Problemlösefähigkeiten im Vorschulalter zu erfassen, werden methodisch vorgestellt und empirisch mit der häuslichen Lernumwelt in Beziehung gesetzt. Die Daten stammen aus dem Verbundprojekt „Lernunterstützung durch kognitive Aktivierung in inklusiven Kitas (KoAkiK)". The ability to successfully cope with challenges and problems in everyday life is considered an essential facet of resilience and protects children and youths throughout their development. Two ways of capturing social-cognitive problem-solving skills in preschool age will first be methodically presented and then empirically related to the home learning environment. The data originate from the joint project "cognitive activation in inclusive child care centers (KoAkiK)". [ABSTRACT FROM AUTHOR]

Copyright of Textilveredlung is the property of Verlag Textilplus AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Aims: Landiolol, an ultra-fast acting super-selective beta-blocker, was investigated for the first time in Europe in a prospective clinical study for the management of supraventricular tachycardia (SVT) among paediatric patients., Methods and Results: The LANDI-PED study was a prospective, multicentre, open-label, uncontrolled phase III study aiming to investigate the efficacy, safety, and pharmacokinetics (PK) of landiolol in paediatric patients. Sixty patients in surgical and non-surgical settings aged ≥1 day to <18 years with SVTs of various aetiologies received landiolol as a continuous intravenous infusion starting with 5 μg/kg/min titrated up to 40 μg/kg/min depending on heart rate (HR) reduction for up to a maximum of 24 h. The primary endpoint was restoration of normal sinus rhythm (NSR) within 210 min of infusion start. The primary endpoint was achieved in 15 (25.0%) patients. A total of 24 (40.0%) patients achieved a HR reduction of at least 20% within 210 min of landiolol infusion. A significant HR reduction was observed within minutes post-infusion, with a mean (±SD) reduction after 210 min of -13.2 (±11.5)% (P < 0.0001) in the overall population. By infusion end, 51.7% of patients achieved HR reduction of at least 20% from baseline and/or NSR conversion. The PK characteristics were consistent with the known profile of landiolol among adults. The most common adverse drug reaction was hypotension (10%)., Conclusion: Landiolol is effective and safe in the treatment of SVTs in the paediatric population as demonstrated by reduction of HR and/or restoring NSR. Landiolol was well tolerated with no novel safety concerns reported., Clinical Trial Registration: EU Clinical Trial Register; EudraCT Number: 2015-001129-17., Competing Interests: Conflict of interest: M.U., S.S, C.C., C.K., K.K., and J.A. are employees of AOP Orphan Pharmaceuticals GmbH. G.K. is a board director of AOP Health International Management AG. All other authors declare no conflicts of interest regarding this publication., (© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Abstract: Cerebral aneurysm (CA), normal pressure hydrocephalus (NPH) with ventriculoperitoneal shunt (VPS), and pyloric stenosis increase the risk of complications related to electroconvulsive therapy (ECT). Whereas there is some evidence for the safety of ECT in patients with CA and NPH with VPS, there is none in patients with pyloric stenosis that increases the risk of aspiration during short anesthesia. A 67-year-old female patient with a small and stable aneurysm of the right anterior cerebral artery, NPH with VPS, and severe pyloric stenosis (as a result of suicidal ingestion of pipe cleaner) suffering from therapy-resistant depression and chronic suicidal tendencies was treated successfully with 15 sessions of ECT. The following measures were taken to increase ECT-related safety and may help physicians in their decision-making process in similar cases: careful risk assessment based on presentation and discussion of the case in an academic multidisciplinary neurovascular team, glycerol trinitrate sublingual spray before short anesthesia and (after development of hypotension) switching to a pro re nata (PRN) medication with urapidil directly after electric stimulation in case of a relevant increase in blood pressure, examination of the VPS after five stimulations, oral administration of 30 mL of sodium citrate (0.3 molar) before ECT to increase the gastric pH, and establishment of a specific diet and fasting plan (generally only liquid oral food, discontinuation of oral food intake 20 hours, and administration of water only 14 hours before ECT)., Competing Interests: The authors have no conflicts of interest or financial disclosures to report., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)